Roszdavnadzor has allowed the Bonkin.AI artificial intelligence service to be used again to analyze medical research. Previously, the supervisory authority suspended its use due to the risk of “causing damage to health.” This was reported to RB.RU by the press service of Medical Screening Systems LLC, which previously consolidated the developer Botkin.AI.
Subscribe to RB.RU on Telegram
Last fall, the registration certificate for the use of Botkin.AI was suspended. Subsequently, Roszdravnadzor reported on the violations detected during the inspection of the service.
In December 2023, BotkinAI developer Intellogik LLC was consolidated by another medical image analysis systems developer, Celsus, Medical Screening Systems LLC.
According to Artem Kapninsky, CEO of Intellogic, after the transaction was completed, the main task was to resolve Bonkin.AI’s certification issues.
“Over the last six months, many meetings have been held with the regulator and the functionality of the company’s artificial intelligence systems has been configured and improved. Obtaining an approval and increasing the functionality of a medical device is, of course, the merit of well-coordinated teamwork, as well as the participation of the certifying body in the process,” Kapninsky explained.
What changes have been made in Botkin.AI.
- We increased the risk class of a medical device from 2B to 3 (the highest);
- The medical product was modified to support new classes of objects useful in CT studies, including consolidation, ground-glass compaction, nodules, and hydrothorax;
- We added functionality to analyze and describe chest x-rays and mammograms.
The press service also reported that, in accordance with the changes made, Celsus is now the provider in the field of machine learning and artificial intelligence as far as the functionality of Botkin.AI is concerned.
Botkin.AI develops artificial intelligence-based software solutions in the field of radiology. The development was created thanks to investments from Rosatom, the Ministry of Industry and Trade, R-Pharm and Tashir. In 2020, Botkin.AI received a registration certificate.
In 2019, Intellogic raised 100 million rubles from various funds and investors. A year later, the company received another 160 million in Series B, whose main investor was Unicorn Capital Partners. The Tashir Medica holding company became a co-investor.
Author:
Natalia Gormaleva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
